Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia
Investigational drug revumenib now under review at FDA for <em>KMT2A</em>-rearranged disease
United States New York Ibrahim Aldoss Junh Choi Grossman School Of Medicine American Society Of Hematology
Source: medpagetoday.com